8-K: Edesa Biotech Enters At-The-Market Offering Agreement, Terminates Previous Agreement

Edesa Biotech has entered into a new at-the-market offering agreement with H.C. Wainwright & Co., while terminating its previous agreement with Canaccord Genuity LLC.

Summary

• Edesa Biotech, Inc. has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell common shares from time to time.
• The aggregate market value of shares eligible for sale under this agreement is currently $3.87 million.
• Edesa will pay Wainwright a commission of 3.0% of the gross proceeds from each sale of shares.
• The company will also reimburse Wainwright for certain expenses up to $50,000, plus $2,500 per due diligence session update.
• The offering will terminate upon the sale of all shares or termination of the agreement.
• Concurrently, Edesa terminated its previous Equity Distribution Agreement with Canaccord Genuity LLC, effective October 3, 2024.
• Under the terminated agreement, Edesa sold 368,309 common shares for approximately $2.0 million.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While it details a capital raise, which can be dilutive, it also shows the company is actively managing its financing options by switching to a new agreement. The terms are standard for this type of offering.

Positives

• The new at-the-market offering agreement provides Edesa with a flexible way to raise capital.
• The company has terminated its previous agreement without incurring any penalties.

Negatives

• The company will incur commission expenses of 3.0% on the gross proceeds from each sale of shares.
• The company will also incur additional expenses of up to $50,000 plus $2,500 per due diligence session update.

Risks

• There is no guarantee that the company will be able to sell all the shares under the new agreement.
• The company's share price could be negatively impacted by the issuance of new shares.
• The company is subject to market risks and may not be able to raise the full $3.87 million.

Future Outlook

The company may sell shares from time to time through H.C. Wainwright & Co., LLC, but is not obligated to sell any shares and may suspend offers at any time. The offering will terminate upon the sale of all shares or termination of the agreement.

Industry Context

At-the-market offerings are a common method for biotech companies to raise capital, providing flexibility and avoiding the need for large, dilutive offerings. The termination of the previous agreement and entry into a new one suggests a strategic shift in the company's approach to capital raising.

Comparison to Industry Standards

• At-the-market offerings are a common practice for small to mid-cap biotech companies like Edesa Biotech, allowing them to raise capital incrementally without significant market disruption.
• The 3% commission rate is within the typical range for such agreements, although it can vary based on the size and risk profile of the company.
• Comparable companies that have used ATM offerings include XOMA Corporation, which raised $100 million in 2023, and Agenus Inc., which has used ATM offerings to fund its clinical trials.
• The $3.87 million offering size is relatively small compared to some other biotech ATM offerings, reflecting Edesa's current capital needs and market capitalization.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may be impacted by the company's financial performance and ability to fund operations.
• Customers and suppliers may not be directly impacted by this announcement.

Next Steps

• Edesa Biotech will sell common shares through H.C. Wainwright & Co., LLC.
• The company will file a prospectus supplement with the SEC.
• The company will monitor market conditions and may suspend sales at any time.

Key Dates

Keywords

at-the-market offering, equity distribution, common shares, capital raise, H.C. Wainwright, Canaccord Genuity, securities, biotech